Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Association between enrollment factors and incident cognitive impairment in Blacks and Whites: Data from the Alzheimer's Disease Center.

Gleason CE, Norton D, Zuelsdorff M, Benton SF, Wyman MF, Nystrom N, Lambrou N, Salazar H, Koscik RL, Jonaitis E, Carter F, Harris B, Gee A, Chin N, Ketchum F, Johnson SC, Edwards DF, Carlsson CM, Kukull W, Asthana S.

Alzheimers Dement. 2019 Oct 6. pii: S1552-5260(19)35138-6. doi: 10.1016/j.jalz.2019.07.015. [Epub ahead of print]

PMID:
31601516
2.

Depressive role impairment and subthreshold depression in older black and white women: race differences in the clinical significance criterion.

Wyman MF, Jonaitis EM, Ward EC, Zuelsdorff M, Gleason CE.

Int Psychogeriatr. 2019 Aug 28:1-13. doi: 10.1017/S1041610219001133. [Epub ahead of print]

PMID:
31455459
3.

The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned?

Miller VM, Naftolin F, Asthana S, Black DM, Brinton EA, Budoff MJ, Cedars MI, Dowling NM, Gleason CE, Hodis HN, Jayachandran M, Kantarci K, Lobo RA, Manson JE, Pal L, Santoro NF, Taylor HS, Harman SM.

Menopause. 2019 Sep;26(9):1071-1084. doi: 10.1097/GME.0000000000001326.

4.

Potassium acts through mTOR to regulate its own secretion.

Sørensen MV, Saha B, Jensen IS, Wu P, Ayasse N, Gleason CE, Svendsen SL, Wang WH, Pearce D.

JCI Insight. 2019 Apr 23;5. pii: 126910. doi: 10.1172/jci.insight.126910.

5.

The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned?

Miller VM, Naftolin F, Asthana S, Black DM, Brinton EA, Budoff MJ, Cedars MI, Dowling NM, Gleason CE, Hodis HN, Jayachandran M, Kantarci K, Lobo RA, Manson JE, Pal L, Santoro NF, Taylor HS, Harman SM.

Menopause. 2019 Apr 1. doi: 10.1097/GME.0000000000001326. [Epub ahead of print]

PMID:
30939537
6.

Phosphorylation at distinct subcellular locations underlies specificity in mTORC2-mediated activation of SGK1 and Akt.

Gleason CE, Oses-Prieto JA, Li KH, Saha B, Situ G, Burlingame AL, Pearce D.

J Cell Sci. 2019 Apr 9;132(7). pii: jcs224931. doi: 10.1242/jcs.224931.

7.

Association of the Haptoglobin Gene Polymorphism With Cognitive Function and Decline in Elderly African American Adults With Type 2 Diabetes: Findings From the Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) Study.

Beeri MS, Lin HM, Sano M, Ravona-Springer R, Liu X, Bendlin BB, Gleason CE, Guerrero-Berroa E, Soleimani L, Launer LJ, Ehrenberg S, Lache O, Seligman YK, Levy AP.

JAMA Netw Open. 2018 Nov 2;1(7):e184458. doi: 10.1001/jamanetworkopen.2018.4458.

8.

Characterizing the Effects of Sex, APOE ɛ4, and Literacy on Mid-life Cognitive Trajectories: Application of Information-Theoretic Model Averaging and Multi-model Inference Techniques to the Wisconsin Registry for Alzheimer's Prevention Study.

Koscik RL, Norton DL, Allison SL, Jonaitis EM, Clark LR, Mueller KD, Hermann BP, Engelman CD, Gleason CE, Sager MA, Chappell RJ, Johnson SC.

J Int Neuropsychol Soc. 2019 Feb;25(2):119-133. doi: 10.1017/S1355617718000954. Epub 2018 Dec 7.

9.

Longitudinal Standards for Mid-life Cognitive Performance: Identifying Abnormal Within-Person Changes in the Wisconsin Registry for Alzheimer's Prevention.

Koscik RL, Jonaitis EM, Clark LR, Mueller KD, Allison SL, Gleason CE, Chappell RJ, Hermann BP, Johnson SC.

J Int Neuropsychol Soc. 2019 Jan;25(1):1-14. doi: 10.1017/S1355617718000929. Epub 2018 Nov 28.

10.

The recency ratio is related to CSF amyloid beta 1-42 levels in MCI-AD.

Bruno D, Gleason CE, Koscik RL, Pomara N, Zetterberg H, Blennow K, Johnson SC.

Int J Geriatr Psychiatry. 2019 Mar;34(3):415-419. doi: 10.1002/gps.5029. Epub 2018 Dec 10.

PMID:
30430632
11.

Cognitive Changes with Reproductive Aging, Perimenopause, and Menopause.

Morgan KN, Derby CA, Gleason CE.

Obstet Gynecol Clin North Am. 2018 Dec;45(4):751-763. doi: 10.1016/j.ogc.2018.07.011. Epub 2018 Oct 25. Review.

PMID:
30401555
12.

Dietary carotenoids and cognitive function among US adults, NHANES 2011-2014.

Christensen K, Gleason CE, Mares JA.

Nutr Neurosci. 2018 Oct 16:1-9. doi: 10.1080/1028415X.2018.1533199. [Epub ahead of print]

PMID:
30326796
13.

Apathy in Preclinical Alzheimer's Disease: Psychometric Validation of the Apathy Evaluation Scale.

Umucu E, Wyman M, Lee B, Zuelsdorff M, Benton SF, Nystrom N, Johnson SC, Carlsson CM, Asthana S, Gleason CE.

Am J Alzheimers Dis Other Demen. 2019 Feb;34(1):16-22. doi: 10.1177/1533317518794020. Epub 2018 Aug 14.

PMID:
30103612
14.

Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial.

Kantarci K, Tosakulwong N, Lesnick TG, Zuk SM, Lowe VJ, Fields JA, Gunter JL, Senjem ML, Settell ML, Gleason CE, Shuster LT, Bailey KR, Dowling NM, Asthana S, Jack CR Jr, Rocca WA, Miller VM.

Neurology. 2018 Apr 17;90(16):e1404-e1412. doi: 10.1212/WNL.0000000000005325. Epub 2018 Mar 21.

15.

Non-invasive detection of divergent metabolic signals in insulin deficiency vs. insulin resistance in vivo.

Morze CV, Allu PKR, Chang GY, Marco-Rius I, Milshteyn E, Wang ZJ, Ohliger MA, Gleason CE, Kurhanewicz J, Vigneron DB, Pearce D.

Sci Rep. 2018 Feb 1;8(1):2088. doi: 10.1038/s41598-018-20264-w.

16.

Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker.

Gleason CE, Norton D, Anderson ED, Wahoske M, Washington DT, Umucu E, Koscik RL, Dowling NM, Johnson SC, Carlsson CM, Asthana S; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2018;61(1):79-89. doi: 10.3233/JAD-170498.

17.

Differential Regulation of Lipoprotein and Hepatitis C Virus Secretion by Rab1b.

Takacs CN, Andreo U, Dao Thi VL, Wu X, Gleason CE, Itano MS, Spitz-Becker GS, Belote RL, Hedin BR, Scull MA, Rice CM, Simon SM.

Cell Rep. 2017 Oct 10;21(2):431-441. doi: 10.1016/j.celrep.2017.09.053.

18.

An Examination of Brain Abnormalities and Mobility in Individuals with Mild Cognitive Impairment and Alzheimer's Disease.

Fischer BL, Bacher R, Bendlin BB, Birdsill AC, Ly M, Hoscheidt SM, Chappell RJ, Mahoney JE, Gleason CE.

Front Aging Neurosci. 2017 Apr 5;9:86. doi: 10.3389/fnagi.2017.00086. eCollection 2017.

19.

Green fluorescent protein-tagged apolipoprotein E: A useful marker for the study of hepatic lipoprotein egress.

Takacs CN, Andreo U, Belote RL, Pulupa J, Scull MA, Gleason CE, Rice CM, Simon SM.

Traffic. 2017 Mar;18(3):192-204. doi: 10.1111/tra.12467. Epub 2017 Jan 31.

20.

Intraindividual Cognitive Variability in Middle Age Predicts Cognitive Impairment 8-10 Years Later: Results from the Wisconsin Registry for Alzheimer's Prevention.

Koscik RL, Berman SE, Clark LR, Mueller KD, Okonkwo OC, Gleason CE, Hermann BP, Sager MA, Johnson SC.

J Int Neuropsychol Soc. 2016 Nov;22(10):1016-1025.

21.

Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study.

Santoro N, Allshouse A, Neal-Perry G, Pal L, Lobo RA, Naftolin F, Black DM, Brinton EA, Budoff MJ, Cedars MI, Dowling NM, Dunn M, Gleason CE, Hodis HN, Isaac B, Magnani M, Manson JE, Miller VM, Taylor HS, Wharton W, Wolff E, Zepeda V, Harman SM.

Menopause. 2017 Mar;24(3):238-246. doi: 10.1097/GME.0000000000000756.

22.

Cognitive variability-A marker for incident MCI and AD: An analysis for the Alzheimer's Disease Neuroimaging Initiative.

Anderson ED, Wahoske M, Huber M, Norton D, Li Z, Koscik RL, Umucu E, Johnson SC, Jones J, Asthana S, Gleason CE; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement (Amst). 2016 May 26;4:47-55. doi: 10.1016/j.dadm.2016.05.003. eCollection 2016.

23.

Effects of hormone therapy on brain structure: A randomized controlled trial.

Kantarci K, Tosakulwong N, Lesnick TG, Zuk SM, Gunter JL, Gleason CE, Wharton W, Dowling NM, Vemuri P, Senjem ML, Shuster LT, Bailey KR, Rocca WA, Jack CR Jr, Asthana S, Miller VM.

Neurology. 2016 Aug 30;87(9):887-96. doi: 10.1212/WNL.0000000000002970. Epub 2016 Jul 29.

24.

Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife.

Racine AM, Koscik RL, Berman SE, Nicholas CR, Clark LR, Okonkwo OC, Rowley HA, Asthana S, Bendlin BB, Blennow K, Zetterberg H, Gleason CE, Carlsson CM, Johnson SC.

Brain. 2016 Aug;139(Pt 8):2261-74. doi: 10.1093/brain/aww142. Epub 2016 Jun 20.

25.

Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults.

Hoscheidt SM, Starks EJ, Oh JM, Zetterberg H, Blennow K, Krause RA, Gleason CE, Puglielli L, Atwood CS, Carlsson CM, Asthana S, Johnson SC, Bendlin BB.

J Alzheimers Dis. 2016 Apr 12;52(4):1373-83. doi: 10.3233/JAD-160110.

26.

Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.

Melah KE, Lu SY, Hoscheidt SM, Alexander AL, Adluru N, Destiche DJ, Carlsson CM, Zetterberg H, Blennow K, Okonkwo OC, Gleason CE, Dowling NM, Bratzke LC, Rowley HA, Sager MA, Asthana S, Johnson SC, Bendlin BB.

J Alzheimers Dis. 2016;50(3):873-86. doi: 10.3233/JAD-150897.

27.

Common Sense Model Factors Affecting African Americans' Willingness to Consult a Healthcare Provider Regarding Symptoms of Mild Cognitive Impairment.

Gleason CE, Dowling NM, Benton SF, Kaseroff A, Gunn W, Edwards DF.

Am J Geriatr Psychiatry. 2016 Jul;24(7):537-46. doi: 10.1016/j.jagp.2015.08.005. Epub 2015 Sep 14.

28.

Differential effects of hormone therapy on serotonin, vascular function and mood in the KEEPS.

Raz L, Hunter LV, Dowling NM, Wharton W, Gleason CE, Jayachandran M, Anderson L, Asthana S, Miller VM.

Climacteric. 2016;19(1):49-59. doi: 10.3109/13697137.2015.1116504. Epub 2015 Dec 10.

29.

Cognitive Effects of Soy Isoflavones in Patients with Alzheimer's Disease.

Gleason CE, Fischer BL, Dowling NM, Setchell KD, Atwood CS, Carlsson CM, Asthana S.

J Alzheimers Dis. 2015;47(4):1009-19. doi: 10.3233/JAD-142958.

30.

Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study.

Gleason CE, Dowling NM, Wharton W, Manson JE, Miller VM, Atwood CS, Brinton EA, Cedars MI, Lobo RA, Merriam GR, Neal-Perry G, Santoro NF, Taylor HS, Black DM, Budoff MJ, Hodis HN, Naftolin F, Harman SM, Asthana S.

PLoS Med. 2015 Jun 2;12(6):e1001833; discussion e1001833. doi: 10.1371/journal.pmed.1001833. eCollection 2015 Jun.

31.

Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease.

Almeida RP, Schultz SA, Austin BP, Boots EA, Dowling NM, Gleason CE, Bendlin BB, Sager MA, Hermann BP, Zetterberg H, Carlsson CM, Johnson SC, Asthana S, Okonkwo OC.

JAMA Neurol. 2015 Jun;72(6):699-706. doi: 10.1001/jamaneurol.2015.0098.

32.

Insulin Resistance is Associated with Higher Cerebrospinal Fluid Tau Levels in Asymptomatic APOEɛ4 Carriers.

Starks EJ, Patrick O'Grady J, Hoscheidt SM, Racine AM, Carlsson CM, Zetterberg H, Blennow K, Okonkwo OC, Puglielli L, Asthana S, Dowling NM, Gleason CE, Anderson RM, Davenport-Sis NJ, DeRungs LM, Sager MA, Johnson SC, Bendlin BB.

J Alzheimers Dis. 2015;46(2):525-33. doi: 10.3233/JAD-150072.

33.

The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function.

Dowling NM, Johnson SC, Gleason CE, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2015 Jan 15;105:357-68. doi: 10.1016/j.neuroimage.2014.10.050. Epub 2014 Oct 29.

34.

mTORC2 regulates renal tubule sodium uptake by promoting ENaC activity.

Gleason CE, Frindt G, Cheng CJ, Ng M, Kidwai A, Rashmi P, Lang F, Baum M, Palmer LG, Pearce D.

J Clin Invest. 2015 Jan;125(1):117-28. doi: 10.1172/JCI73935. Epub 2014 Nov 21.

35.

Cerebrospinal fluid sphingolipids, β-amyloid, and tau in adults at risk for Alzheimer's disease.

Mielke MM, Haughey NJ, Bandaru VVR, Zetterberg H, Blennow K, Andreasson U, Johnson SC, Gleason CE, Blazel HM, Puglielli L, Sager MA, Asthana S, Carlsson CM.

Neurobiol Aging. 2014 Nov;35(11):2486-2494. doi: 10.1016/j.neurobiolaging.2014.05.019. Epub 2014 May 27.

36.

Performance-based assessment of falls risk in older veterans with executive dysfunction.

Fischer BL, Hoyt WT, Maucieri L, Kind AJ, Gunter-Hunt G, Swader TC, Gangnon RE, Gleason CE.

J Rehabil Res Dev. 2014;51(2):263-74. doi: 10.1682/JRRD.2013.03.0075.

37.

Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis.

Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M, Thomas AG, Gleason CE, Tatonetti NP, Slusher BS, Stockwell BR.

Elife. 2014 May 20;3:e02523. doi: 10.7554/eLife.02523.

38.

Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.

Honeyman JN, Simon EP, Robine N, Chiaroni-Clarke R, Darcy DG, Lim II, Gleason CE, Murphy JM, Rosenberg BR, Teegan L, Takacs CN, Botero S, Belote R, Germer S, Emde AK, Vacic V, Bhanot U, LaQuaglia MP, Simon SM.

Science. 2014 Feb 28;343(6174):1010-4. doi: 10.1126/science.1249484.

39.

The KEEPS-Cognitive and Affective Study: baseline associations between vascular risk factors and cognition.

Wharton W, Gleason CE, Dowling NM, Carlsson CM, Brinton EA, Santoro MN, Neal-Perry G, Taylor H, Naftolin F, Lobo RA, Merriam G, Manson JE, Cedars MI, Miller VM, Black DM, Budoff M, Hodis HN, Harman SM, Asthana S.

J Alzheimers Dis. 2014;40(2):331-41. doi: 10.3233/JAD-130245.

40.

Declining cognition and falls: role of risky performance of everyday mobility activities.

Fischer BL, Gleason CE, Gangnon RE, Janczewski J, Shea T, Mahoney JE.

Phys Ther. 2014 Mar;94(3):355-62. doi: 10.2522/ptj.20130195. Epub 2013 Nov 14.

41.

Neurobiological Underpinnings of the Estrogen - Mood Relationship.

Wharton W, Gleason CE, Olson SR, Carlsson CM, Asthana S.

Curr Psychiatry Rev. 2012 Aug 1;8(3):247-256.

42.

Characterization of vascular disease risk in postmenopausal women and its association with cognitive performance.

Dowling NM, Gleason CE, Manson JE, Hodis HN, Miller VM, Brinton EA, Neal-Perry G, Santoro MN, Cedars M, Lobo R, Merriam GR, Wharton W, Naftolin F, Taylor H, Harman SM, Asthana S.

PLoS One. 2013 Jul 17;8(7):e68741. doi: 10.1371/journal.pone.0068741. Print 2013.

43.

Rationale and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS Cognitive and Affective sub study (KEEPS Cog).

Wharton W, Gleason CE, Miller VM, Asthana S.

Brain Res. 2013 Jun 13;1514:12-7. doi: 10.1016/j.brainres.2013.04.011. Epub 2013 Apr 17.

44.

Caring for older adults with mild cognitive impairment: an update for nurses.

Lin F, Vance DE, Gleason CE, Heidrich SM.

J Gerontol Nurs. 2012 Dec;38(12):22-35; quiz 36-7. doi: 10.3928/00989134-20121106-02.

45.

Longer duration of hormonal contraceptive use predicts better cognitive outcomes later in life.

Egan KR, Gleason CE.

J Womens Health (Larchmt). 2012 Dec;21(12):1259-66. doi: 10.1089/jwh.2012.3522. Epub 2012 Sep 20.

46.

The effects of ramipril in individuals at risk for Alzheimer's disease: results of a pilot clinical trial.

Wharton W, Stein JH, Korcarz C, Sachs J, Olson SR, Zetterberg H, Dowling M, Ye S, Gleason CE, Underbakke G, Jacobson LE, Johnson SC, Sager MA, Asthana S, Carlsson CM.

J Alzheimers Dis. 2012;32(1):147-56.

47.

Illness representations in older adults with mild cognitive impairment.

Lin F, Gleason CE, Heidrich SM.

Res Gerontol Nurs. 2012 Jul;5(3):195-206. doi: 10.3928/19404921-20120605-04. Epub 2012 Jun 15.

48.

Ferroptosis: an iron-dependent form of nonapoptotic cell death.

Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B 3rd, Stockwell BR.

Cell. 2012 May 25;149(5):1060-72. doi: 10.1016/j.cell.2012.03.042.

49.

Using predictors of hormone therapy use to model the healthy user bias: how does healthy user status influence cognitive effects of hormone therapy?

Gleason CE, Dowling NM, Friedman E, Wharton W, Asthana S.

Menopause. 2012 May;19(5):524-33. doi: 10.1097/gme.0b013e318238ff2c.

50.

Loss of Akt1 in mice increases energy expenditure and protects against diet-induced obesity.

Wan M, Easton RM, Gleason CE, Monks BR, Ueki K, Kahn CR, Birnbaum MJ.

Mol Cell Biol. 2012 Jan;32(1):96-106. doi: 10.1128/MCB.05806-11. Epub 2011 Oct 28.

Supplemental Content

Loading ...
Support Center